Back to search

Article

Concurrent afatinib and stereotactic body radiotherapy improved survival of patient with oligometastatic EGFR-mutated non-small cell lung cancer： A case study and literature review

2024-03-07

Abstract excerpt

<h4>Background: </h4> Epidermal growth factor receptor (EGFR) mutated patients treated with target therapy are inevitable to develop resistance to tyrosine kinase inhibitors (TKIs). It has recently been proved that concurrent stereotactic body radiotherapy (SBRT) and the first-generation TKIs can prolong both progression-free survival (PFS) and overall survival (OS) of EGFR-mutated patients with limited metastases...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1fc150b8-848e-55ed-821c-7d7e63c74e8a
DOI
10.21203/rs.3.rs-4008136/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Concurrent afatinib and stereotactic body radiotherapy improved survival of patient with oligometastatic EGFR-mutated non-small cell lung cancer： A case study and literature reviewDOI 10.21203/rs.3.rs-4008136/v1
EGFR-TKIs with or without Stereotactic Body Radiotherapy to Primary Lesion in the Advanced EGFR-Mutated Non- Small Cell Lung CancerSemantic proximity
Safety and efficacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after first-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trialSemantic proximity
Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique.Semantic proximity
EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study.Semantic proximity
Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non-small-cell lung cancer: a propensity-matched retrospective study.Semantic proximity
Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases.Semantic proximity
Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kinase Inhibitors.Semantic proximity
A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11).Semantic proximity
Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study.Semantic proximity
The Optimal Therapeutic Strategy for Patients with EGFR-Mutated Non–Small Cell Lung Cancer with Brain Metastasis: A Real-World Study from TaiwanSemantic proximity
Complete Response to Immunotherapy Plus Chemotherapy After an Unusual Clinical Response to Afatinib and Stereotactic Radiosurgery in a Patient With Metastatic EGFR-Mutant Non-Small-Cell Lung Cancer.Semantic proximity
Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan.Semantic proximity
Select a neighboring publication to make it the new centre.